A combination treatment of lurbinectedin, also known as Zepzelca, and atezolizumab, also known as Tecentriq, has been approved for maintenance therapy in extensive-stage small cell lung cancer. The approval is for first-line maintenance treatment, although the specific details of the approval, including the regulatory body involved, are not consistent across reports. The treatment involves the use of lurbinectedin and atezolizumab together for this type of cancer.